Attachment for an inhaler
Latest Novartis AG Patents:
- Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
- CD19 and CD22 chimeric antigen receptors and uses thereof
- Tricyclic AKR1C3 dependent KARS inhibitors
- Treatment of cancer using GFR alpha-4 chimeric antigen receptor
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins
Description
FIG. 1 perspective view
FIG. 2 front view, wherein the rear view of FIG. 2 is not part of the claimed invention.
FIG. 3 side view of FIG. 2; and,
FIG. 4 plan view of FIG. 2.
The broken line showing of the inhaler and the rear of portion of the attachment are for illustrative purposes only and forms no part of the claimed design.
Referenced Cited
Patent History
Patent number: D420736
Type: Grant
Filed: Dec 22, 1997
Date of Patent: Feb 15, 2000
Assignee: Novartis AG (Basel)
Inventor: Claude Moulin (Rheinfelden)
Primary Examiner: Louis S. Zarfas
Assistant Examiner: I Simmons
Attorneys: William K. Wissing, Stephen G. Kalinchak
Application Number: 0/80,997
Type: Grant
Filed: Dec 22, 1997
Date of Patent: Feb 15, 2000
Assignee: Novartis AG (Basel)
Inventor: Claude Moulin (Rheinfelden)
Primary Examiner: Louis S. Zarfas
Assistant Examiner: I Simmons
Attorneys: William K. Wissing, Stephen G. Kalinchak
Application Number: 0/80,997
Classifications
Current U.S. Class:
Respirator, Vaporizer, Or Inhalation Tube (4) (D24/110)
International Classification: 2902;
International Classification: 2902;